With regard to T2DM, Harter et al., observed that individuals with T2DM on insulin treatment exhibited lower fasting amylin levels, as expected considering that exogenous insulin suppresses b-cell insulin/amylin co-excretion, while subjects on oral antidiabetic medications had higher basal amylin values than the control group [188]. This evidence concerns the gene INS and type 2 diabetes mellitus.